Detailed Information

Cited 26 time in webofscience Cited 37 time in scopus
Metadata Downloads

Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase

Authors
Lee, Han AhLee, Hyun WoongKim, In HeePark, Soo YoungSinn, Dong HyunYu, Jung HwanSeo, Yeon SeokUm, Soon HoLee, Jung IlLee, Kwan SikLee, Chang HunTak, Won YoungKweon, Young OhKang, WonseokPaik, Yong-HanLee, Jin-WooSuh, Sang JunJung, Young KulKim, Beom KyungPark, Jun YongKim, YoungAhn, Sang HoonHan, Kwang-HyubYim, Hyung JoonKim, Seung Up
Issue Date
Jul-2020
Publisher
WILEY
Citation
Alimentary Pharmacology and Therapeutics, v.52, no.1, pp.196 - 204
Indexed
SCIE
SCOPUS
Journal Title
Alimentary Pharmacology and Therapeutics
Volume
52
Number
1
Start Page
196
End Page
204
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/28054
DOI
10.1111/apt.15741
ISSN
0269-2813
Abstract
Background Anti-viral therapy is not indicated for patients with chronic hepatitis B (CHB) in the immune-tolerant phase. Aims To investigate the cumulative incidence of phase change and hepatocellular carcinoma (HCC) and independent predictors for phase change in patients with CHB in immune-tolerant phase. Methods In total, 946 patients in immune-tolerant phase, defined as hepatitis B e antigen positivity, HBV-DNA >20 000 IU/mL and alanine aminotransferase (ALT) <= 40 IU/L, between 1989 and 2017 were enrolled from eight institutes. Results The mean age of study population (429 men and 517 women) was 36.7 years. The mean ALT and HBV-DNA levels were 24.6 IU/L and 8.50 log(10) IU/mL, respectively. Of the study population, 476 (50.3%) patients remained in immune-tolerant phase throughout the study period (median: 63.6 months). The cumulative incidence rates of phase change and HCC at 10 years were 70.7% and 1.7%, respectively. Multivariate analyses revealed that HBV-DNA level >10(7) IU/mL was associated independently with a reduced risk of phase change (hazard ratio [HR] = 0.734, P = 0.008), whereas a high ALT level, above the cut-off recommended in the Korean Association for the Study of the Liver guidelines (34 IU/L for men and 30 IU/L for women), was associated independently with a greater risk of phase change (HR = 1.885, P < 0.001). Conclusions The criterion of HBV-DNA level > 10(7) IU/mL may be useful to define immune-tolerant phase. In addition, an extremely low risk of HCC development was observed in patients with CHB in immune-tolerant phase.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Jung, Young Kul photo

Jung, Young Kul
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE